Science, sustainability and momentum are our guiding principles and influence all areas of our work. Our mission is to make a sustainable contribution to global women´s health.
For Gedea Biotech, sustainability is a core activity. According to the World Health Organization (WHO), antibiotic resistance is a growing problem and one of the biggest threats to global public health. Our business concept is to develop a preferred, effective and antibiotic-free treatment to solve the problem with vaginal infections and their complications. Clinical trials are currently ongoing and we are gearing up for a product launch. Everything points to pHyph having the potential to make a real impact on a market with a high medical need.
Gedea Biotech was set up by a multidisciplinary team from Lund University. The broad competence of our employees is the basis for our success. Since the company was formed in 2015, we have been fortunate to receive a number of awards, making us even prouder of what we have achieved so far.
Annette has an executive management education from Executive Foundation Lund (EFL), a PhD in Medicine from Lund University as well as a Master's degree in Medical Biology from Linköping University. She has over 10 years of experience from project management and business development positions in privately held, listed biotech companies and the healthcare sector.
+46 (0) 708 - 91 86 81
Project and Communications Manager
Birgit holds a PhD in molecular cell biology and Nutrition and a Master’s in Biology from Lund University and has over 10 years of experience within scientific writing, validations and product development in the biotech field.
+46 (0) 70-513 16 81
Ekaterina has PhD in bioinorganic chemistry from Lund University and a Master’s degree in Chemistry from Moscow State University. Ekaterina has over 10 years of experience in product development, product improvements, vigilance, quality management systems, clinical and regulatory support for new product development projects and global product registrations from several medical device companies. Ekaterina is a certified Quality Auditor ISO 13485, ISO 9001, IVDD/IVDR, MDD/MDR, QSR and MDSAP.
Sten has a Degree of Master of Science in Pharmacy from University of Uppsala. He has held positions as clinical trials manager and project manager for over 25 years. He has extensive experience from developing pharmaceutical products and medical devices.
Ton holds a B.Econ from Saxion University of Applied Sciences and a Life Science industry Diploma from PwC / Harvard Business School / IMD. Ton Berkien's expertise is within in leadership, business development and M&A. Since December 2020, he is Chief Business Officer (CBO) at Ultimovacs ASA (Norway). Prior to joining Ultimovacs he was CBO at Nuevolution A/S and Director Global Transactions at Amgen. Further he has experience from, among others, Takeda / Nycomed as Sr. Director of Corporate Development and M&A.
Olov is Professor emeritus in Organic Chemistry at Lund University. He has extensive experience in starting and running innovative life science companies. Olov is co-founder of Selcis biopharma, De-NovaStella AB, Respiratorius AB, Gabather AB and Glactone AB.
Helena is Associate Professor and a Senior Consultant at the Department of Obstetrics and Gynecology at Lund University and Skåne University Hospital in Lund. As Medical Officer at Gedea, she is responsible for clinical trials and questions regarding use of the product. Helena has many years of experience in treating vaginal infections and their complications in clinical work.
Sophie has a PhD in organic chemistry and works as a researcher at Lund University. She is responsible for laboratory research and formulation within Gedea.
Ulf is Professor of Bioorganic Chemistry at Lund University. His research is focused on design and synthesis of carbohydrates in biological systems. Apart from the commitment in Gedea AB, he is founder of Molecular Knowledge AB, as well as an author of popular science.
Peter Enberg has a Bachelor of Business Administration (BBA) from Lund University. Peter started his career as a trainee and then Product Manager at Unilever. In 1992 he started a company for advertising on shopping charts, with 200 stores in Sweden and 80 employees that worked part time as ad-replacers. In 2004 he and two companions bought out Kung Markatta from Svenska Lantmännen and Peter stayed at Kung Markatta as CEO until 2012. As an investor, Peter has invested in 20 startups and is or has been in the board of eight companies, among them Internatural, Speximo and Accumbo.
Mats has over 35 years of experience in managerial and commercial business in the global pharmaceutical industry. Mats worked for Astellas Pharma, where he has been the General Manager for the Nordic and Baltic countries for the past 13 years, and most recently Head of Tesaro in Nordic 2018-19. He has long experience from senior positions in Novo Nordisk, Pharmacia Corporation and Ferring International. Today, besides board member in start-up companies within Life Science sector, also commercial consultancy roles in Life Science.
Per has a PhD in Medical Science and holds a Bachelor's Degree in Analytical Chemistry and Biochemistry from Lund University. As Investment Manager at Almi Invest, Per has long experience of business development and investment in start-up companies, preferably in life science. He has had several roles in pharmaceutical and biotechnology companies. Per is currently a board member of two other start-up companies in life science.
Stina has a PhD in applied biochemistry and has 40 years of experience in research, development, management and board work in Scandinavian life science companies. As an entrepreneur, Stina has worked with research, development, manufacturing and regulatory issues within Biora AB. Stina has also been Vice President of Medicon Valley Alliance and offers evaluation services to RDI sponsors via SigridScience.
EIT Health Catapult third prize and
The Public´s award 2018
Fast Track to Innovation 2020
Crowd Awards September 2017
Grant from Horizon 2020
SME Instruments 2019
Game Changer Maj 2017